Drugs / AV608
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00316550 | Apr 2006 → Jun 2007 | irritable bowel syndrome | Avera Pharmaceuticals | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00335660 | Jun 2006 → Jun 2007 | overactive bladder | Avera Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00294346 | Feb → Dec 2006 | social phobia | Avera Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00316550 ↗ |
| Action | Inhibit | “AV608 is an NK-1 receptor antagonist” NCT00294346 ↗ |
| Route | Oral | “after oral administration” NCT00294346 ↗ |